The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

As Novo Nordisk’s weight-loss pill Wegovy (semaglutide) readies for a launch in the United States early January, it will be a ...

The drugs' high prices, along with spotty insurance coverage, have left them out of reach for many Americans. Read more at ...

The FDA has approved Wegovy (semaglutide) tablets, the first oral GLP-1 receptor agonist for the treatment of obesity.

Hyderabad: Global pharma heavyweights Eli Lilly and Novo Nordisk are racing to lock in market leadership in India’s blooming ...

A new study uses shopping receipts to show how appetite changes from Ozempic and Wegovy affect grocery and restaurant ...

The Danish drugmaker will start selling a pill version of its Wegovy weight-loss medicine in January, after [securing ...

The FDA is expected to issue a decision on Vanda’s Tradipitant, a motion-sickness treatment aimed at preventing vomiting, on ...

In a significant development for global health, U.S. regulators have approved an oral version of the Wegovy weight-loss drug, marking the first time this powerful treatment will be available in pill ...

Researchers will test the drugs against the disease after finding prostate cancer cells were more likely to duplicate and ...

U.S. regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity. The U.S. Food and Drug Administration’s ...

Since early August, the world’s most valuable pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), has put on a stellar ...